France's Ipsen says Dysport incontinence treatment trial positive
PARIS (Reuters) - French drugmaker Ipsen said it had seen positive results from the first stage of a phase II trial of its Dysport brand in treating patients with a certain type of urinary incontinence.
Ipsen said that there had been a mean reduction of more than 75 percent in urinary incontinence episodes for trial patients suffering from neurogenic detrusor overactivity, a chronic condition involving abnormal bladder contractions linked to an underlying neurological condition such as multiple sclerosis.
"These results are very encouraging for the Dysport franchise, which has the opportunity of potentially expanding into urology," Ipsen said.
(Reporting by Lionel Laurent; Editing by John Stonestreet)
- French warplanes search Mali desert for crashed Air Algerie plane
- At least 15 die in Israeli shelling of Gaza school as toll exceeds 750 |
- Exclusive: Ukraine rebel commander acknowledges fighters had BUK missile
- Sierra Leone's chief Ebola doctor contracts the virus
- Minnesota man asked to leave Southwest flight after critical tweet
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video